



*For immediate release 7.00am: 8 May 2015*

**HVIVO PLC**  
("hVIVO" or the "Company")

**Director's dealings**

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, was notified yesterday that on 6 May 2015, Jim Winschel, a Non-Executive Director of the Company, purchased 8,000 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 321.6 pence per share.

Following this transaction, Mr Winschel's total interest in the Company has increased by 8,000 Ordinary Shares to a total of 23,702 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.

**For further information please contact:**

**hVIVO plc**

+44 207 756 1300

Kym Denny (Chief Executive Officer)  
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

**Numis Securities Limited**

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)  
James Black / Michael Burke (Corporate Broking)

**Notes to Editors:**

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.